Seres Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MCRB research report →
Companywww.serestherapeutics.com
Seres Therapeutics, Inc. , a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI).
- CEO
- Richard N. Kender
- IPO
- 2015
- Employees
- 103
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $74.18M
- P/E
- -1.57
- P/S
- 64.67
- P/B
- 2.77
- EV/EBITDA
- -2.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -20.92%
- Op Margin
- -7640.98%
- Net Margin
- -4088.84%
- ROE
- -127.30%
- ROIC
- -80.30%
Growth & Income
- Revenue
- $789.00K · 0.00%
- Net Income
- $5.70M · 103.89%
- EPS
- $0.64 · 103.39%
- Op Income
- $-93,971,000
- FCF YoY
- 100.58%
Performance & Tape
- 52W High
- $29.98
- 52W Low
- $6.56
- 50D MA
- $8.38
- 200D MA
- $14.14
- Beta
- 0.12
- Avg Volume
- 48.92K
Get TickerSpark's AI analysis on MCRB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 15, 26 | Shaff Eric D. | other | 722 |
| May 18, 26 | Shaff Eric D. | sell | 259 |
| May 15, 26 | DesRosier Thomas | other | 244 |
| May 18, 26 | DesRosier Thomas | sell | 79 |
| May 15, 26 | Shaff Eric D. | other | 331 |
| May 15, 26 | Shaff Eric D. | other | 391 |
| May 15, 26 | DesRosier Thomas | other | 111 |
| May 15, 26 | DesRosier Thomas | other | 133 |
| May 15, 26 | Brady Kelly | other | 180 |
| May 18, 26 | Brady Kelly | sell | 59 |
Our MCRB Coverage
We haven't published any research on MCRB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MCRB Report →